Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration.
about
Molecular characterization of a B-ring unsaturated estrogen: Implications for conjugated equine estrogen components of PremarinBioidentical hormone therapyEthical problems with bioidentical hormone therapyDisorders of bone remodelingThe cognitive effects of conjugated equine estrogens depend on whether menopause etiology is transitional or surgical.Remarkable change in age-specific breast cancer incidence in the Swiss canton of Geneva and its possible relation with the use of hormone replacement therapyChanges of the prescription of hormone therapy in menopausal women: an observational study in Taiwan.Endometrial cancer in Puerto Rico: incidence, mortality and survival (1992-2003)Long-term postmenopausal hormone therapy and endometrial cancerDevelopment of cell-based high-throughput assays for the identification of inhibitors of receptor activator of nuclear factor-kappa B signaling.Estrogenic compounds, estrogen receptors and vascular cell signaling in the aging blood vesselsPotential approaches to enhance the effects of estrogen on senescent blood vessels and postmenopausal cardiovascular disease.Selective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis.Menopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study.Menopausal hormone therapy and cancer: changing clinical observations of target site specificity.A component of Premarin(®) enhances multiple cognitive functions and influences nicotinic receptor expression.Estrogen, vascular estrogen receptor and hormone therapy in postmenopausal vascular disease.Impact of sex hormone metabolism on the vascular effects of menopausal hormone therapy in cardiovascular disease.Estradiol and cognitive function: past, present and future.Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009Combined treatment with dexamethasone and raloxifene totally abrogates osteoporosis and joint destruction in experimental postmenopausal arthritis.Oral contraceptives, menopausal hormone therapy use and risk of B-cell non-Hodgkin lymphoma in the California Teachers Study.Vascular effects of phytoestrogens and alternative menopausal hormone therapy in cardiovascular diseaseContinuous estrone treatment impairs spatial memory and does not impact number of basal forebrain cholinergic neurons in the surgically menopausal middle-aged ratMenopause and risk of diabetes in the Diabetes Prevention ProgramReproductive factors and menopausal hormone therapy and bladder cancer risk in the NIH-AARP Diet and Health StudyCurrent and emerging therapies for the treatment of osteoporosisMenopausal hormone therapy for vasomotor symptoms: balancing the risks and benefits with ultra-low doses of estrogen.Hormone therapy and the rise and perhaps fall of US breast cancer incidence rates: critical reflections.Cognitive-impairing effects of medroxyprogesterone acetate in the rat: independent and interactive effects across timeReproductive factors, exogenous hormone use and risk of lymphoid neoplasms among women in the National Institutes of Health-AARP Diet and Health Study Cohort.Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort.Premarin improves memory, prevents scopolamine-induced amnesia and increases number of basal forebrain choline acetyltransferase positive cells in middle-aged surgically menopausal ratsReproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976-2004.Postmenopausal hormone therapy: risks and benefits.Trends in breast cancer incidence and mortality in the United States: implications for prevention.Physiology, production and action of progesterone.Advances in Controlled Drug Delivery for Treatment of OsteoporosisA general description for Chinese medicine in treating premature ovarian failure.Rational combination therapy in refractory migraine.
P2860
Q27648855-9C489971-E3B1-4CBE-A28D-0638BBDC57B8Q27691410-8A5E0AED-53A9-41D7-BEF8-67C5C7E50DFEQ28260821-904AC444-4447-4370-92D4-C8FD4188B924Q28295303-D70FE652-3CCF-4FD7-9E02-F231B7BFDB8EQ30496612-45369827-3F64-46DC-BE26-39D23C3CC218Q33237199-8F45D486-7EA0-4355-9327-0217931DC0CFQ33282313-8687C041-0E05-47D9-A0F6-180CA00E68E9Q33529298-622AF5F2-A7A0-4C0D-8888-E71BE730C5A3Q33650188-9A2E2843-E0E9-45F5-B98C-9970272537DCQ33738074-EA34CB2B-3C79-46B3-AC8B-EFC06A2694B5Q33781367-8F28D2B4-4C65-498B-B269-02F7EF893F12Q33786755-3CE27241-BD6D-49EA-A2A9-076DFBF09325Q34090842-0DFA06CE-FF9E-44FB-A9A0-BEB865AE9B7FQ34115930-F096C2CA-30BF-44D2-955B-D94FFDDB2CDCQ34315478-93A5DB50-BAAB-47B1-8312-CB140D4871E6Q34316221-60BB4580-6AD2-4C97-8EF2-67D6E0A65D9FQ34375771-ACCB592A-3D6C-4AAB-AEF6-A6AB88C2D2D3Q34712250-6BCD493A-104B-48A1-A8EE-A068CEEA9BE2Q35054370-4684208F-BEB8-40FB-812E-16775AAFAAA6Q35068765-695C95FA-5305-4942-8276-0522DCC5CD4CQ35557927-5F2B0A14-D268-4E7F-AFAE-B0A66391590EQ35673920-9DD2DBC2-E0CE-439A-8B51-4A12E4E2408CQ35783517-91C820F8-6E30-4C7E-8288-1CE1D795E169Q36095863-9D1DE92C-3902-4A96-BDAE-0ABB77EA1249Q36407356-402ADCEC-7DDF-4E11-B19F-D6D1B1ED445EQ36823814-EAB3816F-748D-4F66-8125-8B7F18FEE32DQ36890431-BBFF6D73-D9D3-448A-B021-A81EBFB07CCBQ37016116-9F738B3B-10ED-4A36-B5D9-9CEC15E8D02EQ37122762-90A7D5B4-438F-4F44-B607-79126A79A3EFQ37207741-C89900FF-5779-409E-BF21-C45D46DD445DQ37239336-4ABEE080-FD9E-4CC7-B5A9-564A8D59BB98Q37370478-9C7E9E4C-ADF4-4110-9522-867531EE0E96Q37417828-B915A931-A327-4C25-AE1B-9E84F5AEB55AQ37442687-1B101957-56E7-4133-AF55-CF961C3EF6EEQ38082563-6B5F0C7B-9E1F-456F-B559-BC5CD03F14B7Q38094973-D6656696-1D0A-452E-B6AD-29CB7674F291Q38584393-4350754C-4835-41F9-A68F-82F58D08F624Q38922086-266C95BA-A689-4E7A-8CFA-0DD18AE64FC6Q39164979-96CD8A84-92A0-438D-BDED-622971FDDBCDQ40081930-64B165BC-4428-4854-A4BB-366F0EA1FF46
P2860
Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Estrogens and progestins: back ...... Food and Drug Administration.
@ast
Estrogens and progestins: back ...... Food and Drug Administration.
@en
type
label
Estrogens and progestins: back ...... Food and Drug Administration.
@ast
Estrogens and progestins: back ...... Food and Drug Administration.
@en
prefLabel
Estrogens and progestins: back ...... Food and Drug Administration.
@ast
Estrogens and progestins: back ...... Food and Drug Administration.
@en
P1476
Estrogens and progestins: back ...... Food and Drug Administration.
@en
P2093
Marcia L Stefanick
P356
10.1016/J.AMJMED.2005.09.059
P407
P478
118 Suppl 12B
P577
2005-12-01T00:00:00Z